Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1986 Aug;78(2):494-501.
doi: 10.1172/JCI112601.

Identification of a third component of complement-binding glycoprotein of human platelets

Comparative Study

Identification of a third component of complement-binding glycoprotein of human platelets

G H Yu et al. J Clin Invest. 1986 Aug.

Abstract

Utilizing affinity chromatography, a C3-specific binding protein was isolated from 125I surface-labeled human platelets. Analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis demonstrated two bands with mean Mr of 64,000 and 53,000, characteristic variability in the relative density of the two bands in a given individual, and the presence of N-linked complex oligosaccharides as well as sialic acid residues not associated with N-linked sugars. These characteristics are similar to those of a human leukocyte iC3- and C3b-binding glycoprotein, termed gp45-70. Further analysis showed that leukocyte gp45-70 and the platelet C3-binding glycoprotein have identical Mr and other similar structural features. Functional characterization of solubilized platelet preparations indicated that gp45-70 has cofactor activity. This membrane glycoprotein is structurally and antigenically distinct from decay accelerating factor (DAF), a complement regulatory protein previously identified on human platelet membranes. DAF and gp45-70 have complementary activity profiles inasmuch as DAF can prevent assembly of and dissociate the C3 convertases but has no cofactor activity, whereas gp45-70 has cofactor activity but no decay accelerating activity. We suggest that these two proteins function conjointly to prevent autologous complement activation.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Scand J Clin Lab Invest Suppl. 1968;97:77-89 - PubMed
    1. Proc Natl Acad Sci U S A. 1983 Sep;80(18):5699-703 - PubMed
    1. Methods Enzymol. 1974;31:149-55 - PubMed
    1. J Biol Chem. 1979 Apr 10;254(7):2165-7 - PubMed
    1. Proc Natl Acad Sci U S A. 1979 Nov;76(11):5867-71 - PubMed

Publication types